Provider review
NuviaRx review
The narrowest gap between the two molecules of any provider here.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
We may earn a commission at no extra cost to you. Affiliate partners are listed first on our rankings. How we’re funded.
From $140/mo semaglutide and $170/mo tirzepatide
Visit NuviaRxTwo entry figures visible without an intake, and nothing published behind either of them.
Price as published
NuviaRx
From $140/mo semaglutide and $170/mo tirzepatide
- Vs median
- $35/mo below the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Pharmacy not publicly identified
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
Two figures, visible without an intake, and nothing else. That is worth something on its own, because several sellers in this category will not show you a number until you have handed over your details, and this one will. But it is the whole of what is published. There is no ladder, no standing rate, no list of what the figure includes, and no statement of what changes when your dose rises. The genuinely interesting feature is the spread between the two molecules. Thirty dollars a month is the narrowest gap we have come across; the usual step from semaglutide to tirzepatide runs anywhere from a third more to a full doubling, and that step is what catches people who start on one molecule expecting to move to the other. Here that move is close to free, at least at the entry rung. What it costs at a working dose is not published, and no milligram appears against either figure.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You expect to switch molecules and want that step to cost as little as possible
- You want to see a price before handing over any details
- You want both molecules from one provider on the same basis
Look elsewhere if
- You want a ladder, a standing rate or an inclusion list. None is published
- You want to know what a working dose costs
- You want a dose behind the number
What it actually costs
Price as published
From $140/mo semaglutide and $170/mo tirzepatide
- Vs median
- $35/mo below the $175 median across the 299 of 548 programs here that publish a plain monthly rate
- Market
- $59–$1,300/mo is the full published spread on this site
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
235 of the 548 programs here price a small dose this way. Two entry figures visible without an intake and nothing else — no ladder, no standing rate, no inclusion list. What is worth noting is the spread: the step between the two molecules is the narrowest here, where the usual gap runs from a third more to a full doubling. For a reader expecting to switch molecules, that step matters more than the entry price. No low-dose product and no dose published.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not confirmed
- Labs
- Not required
- Pricing
- Check plan terms
What it does well
- Both prices are visible on the front page with no intake required.
- The step from semaglutide to tirzepatide is the narrowest found so far.
- Two molecules offered by one provider on the same basis.
Pharmacy, labs and oversight
NuviaRx does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
2 of 4 published openly
What NuviaRx publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedNo pharmacy is identified anywhere on its own pages.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
Two figures, visible without an intake, and nothing else. That is worth something on its own — a reader can see roughly what this costs before handing over any details, which several sellers here will not allow — but it is the whole of what is published. There is no ladder, no standing rate, no inclusion list and no statement of what happens when the dose rises. The one genuinely interesting feature is the spread between the molecules. Thirty dollars a month is the narrowest gap found so far; the usual step from semaglutide to tirzepatide runs from a third more to a full doubling, which matters to anyone who expects to switch. Here that switch is close to free, at least at the entry rung. What it costs at a working dose is not published, and no milligram appears against either figure.
The honest cons
No ladder, no standing rate and no inclusion list are published.
- Both figures are floors introduced by as low as.
- No milligram appears against either figure.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
NuviaRx is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.
Also consider
Two more programs that price a small dose the way NuviaRx does. Both are partners: we may earn a commission if you start care through these links.
Partner
HealthRX
$190/mo sema · $239/mo tirz (monthly plan)
Standard plan, self-directed low dose
Partner
Sprout Health
$149 sema · $199 tirz
Standard plan, self-directed low dose
FDA warning letter · Sprout Health · September 2025 · addressed to Sprout Health Partners LLC dba Sprout Health. Details in our review.
Where this sits
#320 of 548
Ordered with the companies that pay us first, and NuviaRx is not one of them. A disclosed partition, not a score.
Compare all 548 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Low dose vs full dose
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
$249/mo month to month ($199 on 6-mo)
- Vs median
- $74/mo above the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Compounded by Belmar · Strive · Epiq Scripts · Casa Pharma Rx
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.